Bottneuro secures CHF 4 million to develop its non-invasive Alzheimer's treatment
15.12.2022
The startup, which is developing a non-invasive, home-based treatment for early- and moderate-stage Alzheimer's patients, closed the first tranche of the bridge round, bringing its total capital raised in 2022 to CHF 4 million. The company was awarded CHF 150,000 by Venture Kick in 2021.
 CEO and Co-Founder Bekim Osmani wearing the Bottneuro headset
|
 |
Private and institutional investors such as DART labs, HEMEX, and Zühlke Ventures are supporting Bottneuro in its mission to fight Alzheimer's Disease (AD).
In light of the aging population, this will be one of the biggest challenges of the 21st century. At present, more than 50 million people are affected worldwide; in Europe and the US, a new patient is diagnosed with AD every seven seconds. The disease burden is expected to increase to more than USD 1 trillion annually as global demographics shift. However, there are still only limited treatment options to delay, prevent, or slow this disease.
Research shows that early diagnosis and intervention are key to managing AD. Pre-clinical data suggest that by inducing neuronal oscillations, Aβ plaques and phosphorylated tau can be reduced and that the inflammatory response of microglia can be reversed.
Bottneuro's team at their offices in Basel, including co-founders Dr. Bekim Osmani (CEO) and Dr. Alois C. Hopf (CSO) on the left
Bottneuro contributes to this development with a non-invasive treatment for use at home or in clinical environments. Its innovative method consists of periodic brain stimulation sessions, applied through fully personalized, 3D-printed, wearable headsets. The system integrates software and hardware components, including a large tablet, soft brush electrodes (no shaving needed), and an electronics neckpiece. With this setup, affected brain regions are stimulated externally and the resulting 3D-PET (positron emission tomography) data provides essential information on the areas that are particularly affected.
In 2023, the company will start clinical trials to validate the efficacy of its Miamind® Neurostimulator in Switzerland. It plans to gain regulatory approval by 2025. Besides multiple patents filed, Bottneuro is also acquiring know-how on mass customization of cap design and stimulation patterns for individual patients, making their solution truly unique and difficult to replicate by competition. Thanks to the capital increase, the startup is now in a stable position to accelerate its developments in the coming year.
In 2021, Bottneuro convinced the expert jury of the Venture Kick program and was awarded CHF 150,000. The startup has also secured various academic and industry partnerships, like Samsung and Dätwyler Group as well as other Venture Kick alumni Altoida and Positrigo.
Bottneuro's latest design of a 3D-printed, personalized headset for neuromodulation therapies
(Sources: startupticker.ch/VK)
In light of the aging population, this will be one of the biggest challenges of the 21st century. At present, more than 50 million people are affected worldwide; in Europe and the US, a new patient is diagnosed with AD every seven seconds. The disease burden is expected to increase to more than USD 1 trillion annually as global demographics shift. However, there are still only limited treatment options to delay, prevent, or slow this disease.
Research shows that early diagnosis and intervention are key to managing AD. Pre-clinical data suggest that by inducing neuronal oscillations, Aβ plaques and phosphorylated tau can be reduced and that the inflammatory response of microglia can be reversed.
Bottneuro's team at their offices in Basel, including co-founders Dr. Bekim Osmani (CEO) and Dr. Alois C. Hopf (CSO) on the left
Bottneuro contributes to this development with a non-invasive treatment for use at home or in clinical environments. Its innovative method consists of periodic brain stimulation sessions, applied through fully personalized, 3D-printed, wearable headsets. The system integrates software and hardware components, including a large tablet, soft brush electrodes (no shaving needed), and an electronics neckpiece. With this setup, affected brain regions are stimulated externally and the resulting 3D-PET (positron emission tomography) data provides essential information on the areas that are particularly affected.
In 2023, the company will start clinical trials to validate the efficacy of its Miamind® Neurostimulator in Switzerland. It plans to gain regulatory approval by 2025. Besides multiple patents filed, Bottneuro is also acquiring know-how on mass customization of cap design and stimulation patterns for individual patients, making their solution truly unique and difficult to replicate by competition. Thanks to the capital increase, the startup is now in a stable position to accelerate its developments in the coming year.
In 2021, Bottneuro convinced the expert jury of the Venture Kick program and was awarded CHF 150,000. The startup has also secured various academic and industry partnerships, like Samsung and Dätwyler Group as well as other Venture Kick alumni Altoida and Positrigo.
Bottneuro's latest design of a 3D-printed, personalized headset for neuromodulation therapies
(Sources: startupticker.ch/VK)